(NASDAQ: XNCR) Xencor's forecast annual revenue growth rate of 9.71% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.44%.
Xencor's revenue in 2026 is $125,576,000.On average, 16 Wall Street analysts forecast XNCR's revenue for 2026 to be $9,074,190,175, with the lowest XNCR revenue forecast at $3,574,892,104, and the highest XNCR revenue forecast at $21,506,556,767. On average, 15 Wall Street analysts forecast XNCR's revenue for 2027 to be $9,666,033,016, with the lowest XNCR revenue forecast at $0, and the highest XNCR revenue forecast at $22,146,803,111.
In 2028, XNCR is forecast to generate $12,642,848,494 in revenue, with the lowest revenue forecast at $5,525,186,611 and the highest revenue forecast at $30,355,597,310.